Skip to main content

25-05-2020 | Multiple sclerosis | Video

EAN 2020 | Ocrelizumab benefits in MS extend to patients with previous treatment failure

Bianca Weinstock-Guttman presents the 2-year CHORDS study findings showing good outcomes among patients with relapsing-remitting multiple sclerosis receiving ocrelizumab after a suboptimal response to previous disease-modifying therapy (3:17).

Funding for independent interviews at EAN 2020 was provided by F. Hoffmann-La Roche Ltd, Basel, Switzerland.